In:
Blood, American Society of Hematology, Vol. 130, No. 17 ( 2017-10-26), p. 1903-1910
Abstract:
The intensified standard-of-care regimens for younger patients with MCL do not overcome the deleterious effects of TP53 mutations. MCLs with TP53 mutations should be considered for alternative frontline treatment.
Type of Medium:
Online Resource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood-2017-04-779736
Language:
English
Publisher:
American Society of Hematology
Publication Date:
2017
detail.hit.zdb_id:
1468538-3
detail.hit.zdb_id:
80069-7
Permalink